Wrong! The problem is that when it comes to Anavex there is no credible story for national business/health reporters to cover. Implying that journalists are incompetent, paid dupes is simply wrong. I have to assume that the Barwicki guy pitched national business/health reporters for an exclusive interview with Missling. If everything is so wonderful as many here believe, it should have been like shooting fish in a barrel. The fact that national coverage from even one national business/health reporter didn’t happen simply confirms to me that the Anavex story does not meet even the minimum standards for coverage. Those minimum standards would include, but not be limited to, one or two big pharma partners, top-tier analyst coverage (eg Goldman Sachs or Morgan Stanley, not bucket shops like Dawson James, HC Wainwright or Jones Trading), a top-tier investment bank working on behalf of the company, top-tier biotech investors (not index funds), world renowned, supportive, independent neuroscientists, and peer reviewed papers appearing in top-tier journals like The New England Journal of Medicine.
CTAD exposed Anavex for what it is: A third-tier biotech run by a weak, over-paid CEO who has reached his level of incompetence to the detriment of long term shareholder value. The guy needs to step aside or be pushed out and replaced with a CEO who has the right experience and credibility to take this company forward.
News 
Market Data 
Discover 
AI
